TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB41932

Peptide_Name

Sample Peptide 3 from EP3604345B1

Activity

Anticancer

Activity_category_statistics

Cancer-related peptides

Database_Source

CancerPPD 2.0

Sequence_Type

standard

Has_Modification No

Description A 31-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR-NH2

FASTA

>TPDB41932|Anticancer|length=31
MRIFAVFIFMTYWHLLNAKKRTLRKNDRKKR-NH2

Formula C184H298N56O39S2

Absent Amino Acids CEQGPS

Common Amino Acids RK

Mass 3982.86

PI 12.26

Basic Residues 11

Acidic Residues 1

Hydrophobic Residues 15

Net Charge +9

Boman Index 3.10

Hydrophobicity -0.610

Aliphatic Index 78.71

Half Life

Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 6990

Absorbance 280nm 175.50

Polar Residues 5

number

2

A

5

R

2

N

1

D

0

C

0

E

0

Q

0

G

1

H

2

I

3

L

5

K

2

M

3

F

0

P

0

S

2

T

1

W

1

Y

1

V

Amino Acid Distribution

A: 2 R: 5 N: 2 D: 1 C: 0 E: 0 Q: 0 G: 0 H: 1 I: 2 L: 3 K: 5 M: 2 F: 3 P: 0 S: 0 T: 2 W: 1 Y: 1 V: 1

Length

31

Formula

C184H298N56O39S2

Mass

3982.86

PI

12.26

Net Charge

+9

Boman Index

3.10

Hydrophobicity

-0.610

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Anticancer

Origin

Synthetic

Evidence 1 Activity

Activity

Activity Endpoint Cell Viability

Activity Raw

Cell Viability = 87.7% at 25 µM

Detail Source Activity Anticancer

Target

Cancer Type Lung Cancer

Cell Line NCI-H2444

Tissue Affected Lung

Assay & Model

Assay CCK-8 / WST-8

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023

Patents EP3604345B1

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint Cell Viability

Activity Raw

Cell Viability = 120.6% at 25 µM

Detail Source Activity Anticancer

Target

Cancer Type Lung Cancer

Cell Line HCC-827

Tissue Affected Lung

Assay & Model

Assay CCK-8 / WST-8

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023

Patents EP3604345B1

Evidence 3 Activity

Activity

Activity Endpoint Cell Viability

Activity Raw

Cell Viability = 56.7% at 25 µM

Detail Source Activity Anticancer

Target

Cancer Type Lung Cancer

Cell Line NCI-H446

Tissue Affected Lung

Assay & Model

Assay CCK-8 / WST-8

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023

Patents EP3604345B1

Evidence 4 Activity

Activity

Activity Endpoint Cell Viability

Activity Raw

Cell Viability = 87.5% at 25 µM

Detail Source Activity Anticancer

Target

Cancer Type Skin Cancer

Cell Line A-2058

Tissue Affected Skin

Assay & Model

Assay CCK-8 / WST-8

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023

Patents EP3604345B1

Evidence 5 Activity

Activity

Activity Endpoint Cell Viability

Activity Raw

Cell Viability = 81.7% at 25 µM

Detail Source Activity Anticancer

Target

Cancer Type Breast Cancer

Cell Line MDA-MB-231

Tissue Affected Breast

Assay & Model

Assay CCK-8 / WST-8

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0

Source CancerPPD2

Year 2023

Patents EP3604345B1